Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

When management at a company raises guidance, it can be a catalyst for market-beating returns in the quarters ahead. The second-quarter earnings season is wrapping up, with blended earnings (actual results and the consensus for those still to report) showing a year-over-year gain of 12%, according to Refinitiv. That is considerably better than what was expected at the start of the earnings period. Leading the outperformance are strong gains in Financial, with earnings up 20%. On the flipside, Materials is performing the worst, down 6%. Our analysts are always on the lookout for companies that boost their outlooks during earnings season. Here is a partial list of BUY-rated companies in Argus' Fundamental Universe of Coverage at which management raised guidance or increased its outlook during the 2Q24 EPS reporting season. We like this theme, as it crosses numerous industries and generates a robust list of potential portfolio candidates.

Zoetis Inc., a 2013 spinoff from Pfizer, focuses on the development, manufacture and commercialization of animal health vaccines and medicines, including parasiticides, anti-infectives, and medicated feed additives. The company develops products for both livestock and companion animals and distributes its products globally. Zoetis is a component of the S&P 500 and has roughly 14,100 employees.

U.S. stocks closed higher following new labor market data that gave investors confidence in the economy. The S&P 500 gained 2.3%, its best day since 2022. The Dow advanced 1.76% and the Nasdaq was up 2.87%. Crude oil traded above $76 per barrel and gold rose $35 dollars to $2,467 per ounce.